Orlistat Stada

Orlistat, the active ingredient in Orlistat Stada, is a lipase inhibitor presented as an oral tablet for oral use. It is prescribed to adults with obesity or overweight conditions to aid weight reduction when combined with a reduced‑calorie, low‑fat diet.

GNH USA supplies Orlistat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Our supply chain ensures timely delivery and product integrity across markets.

Orlistat is indicated for weight management in conditions related to excess body fat. - Obesity: helps reduce body weight when used with a reduced‑calorie, low‑fat diet. - Overweight adults with cardiovascular risk factors: supports modest weight loss to improve risk profile. - Weight management in adults: assists in achieving and maintaining weight loss goals as part of a comprehensive lifestyle program.

Orlistat may cause gastrointestinal and metabolic adverse reactions, most of which are related to reduced fat absorption.

Common Side Effects: - Oily spotting: oily discharge on underwear after meals. - Flatulence with discharge: increased gas accompanied by oily stools. - Fecal urgency: sudden need to defecate after eating. - Abdominal discomfort: cramping or mild pain.

Serious or Rare Side Effects: - Severe liver injury: rare cases of hepatitis or liver dysfunction. - Acute kidney injury: very uncommon renal impairment reported.

When prescribing Orlistat, clinicians should consider several safety measures to minimize risks. - Assess eligibility: confirm BMI ≥30 kg/m² or ≥27 kg/m² with obesity‑related comorbidities. - Advise low‑fat diet: recommend a diet containing ≤30% of total calories from fat to reduce gastrointestinal side effects. - Monitor vitamin levels: supplement vitamins A, D, E, K as fat‑soluble absorption may be reduced. - Contraindicated in pregnancy: avoid use during pregnancy and lactation. - Avoid in malabsorption syndromes: patients with chronic malabsorption or cholestasis should not use. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Orlistat can affect the absorption of several concomitant medications, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Cyclosporine: reduced absorption may lower immunosuppressive effect. - Warfarin: increased INR risk due to altered vitamin K absorption. - Levothyroxine: decreased absorption may reduce thyroid hormone efficacy.

Moderate Interactions (Monitor Closely): - Fat‑soluble vitamins (A, D, E, K): supplementation may be needed to prevent deficiency. - Oral contraceptives: efficacy may be reduced; consider alternative or additional contraception. - Antibiotics (e.g., amoxicillin): absorption may be decreased; monitor therapeutic response.